| 1 |
35000525 | Repeated treatments of Capan-1 cells with PARP1 and Chk1 inhibitors promote drug resistance, migration and invasion. | 2022 Dec 31 |
1 |
| 2 |
35051747 | Recent advances in DDR (DNA damage response) inhibitors for cancer therapy. | 2022 Feb 15 |
1 |
| 3 |
33412559 | Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells. | 2021 |
1 |
| 4 |
34131002 | Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors. | 2021 Sep 1 |
1 |
| 5 |
34206543 | Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells. | 2021 Jun 22 |
1 |
| 6 |
33352723 | PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness. | 2020 Dec 19 |
3 |
| 7 |
30201826 | Repurposing of mTOR Complex Inhibitors Attenuates MCL-1 and Sensitizes to PARP Inhibition. | 2019 Jan |
1 |
| 8 |
28490518 | CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib. | 2017 Jul 15 |
1 |
| 9 |
24413181 | Triapine disrupts CtIP-mediated homologous recombination repair and sensitizes ovarian cancer cells to PARP and topoisomerase inhibitors. | 2014 Mar |
1 |
| 10 |
24694947 | New insights into PARP inhibitors' effect on cell cycle and homology-directed DNA damage repair. | 2014 Jun |
1 |
| 11 |
23917378 | PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells. | 2013 May |
1 |